Skip to content
10-K

Annual Report

Grace Therapeutics, Inc. GRCE

0001140361-25-023259

← back to feed
Filed
Jun 23, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · Jun 19, 2025 13.83M sh
Shares Diluted FY 2025 · Mar 31, 2025 12.09M sh
Shares Diluted FY 2025 · Mar 31, 2024 9.53M sh
Operating Cash Flow FY 2025 · Mar 31, 2025 −$14.9M
Operating Cash Flow FY 2025 · Mar 31, 2024 −$12.33M
Cash And Equivalents FY 2025 · Mar 31, 2025 $22.13M
Cash And Equivalents FY 2025 · Mar 31, 2024 $23.01M
Stockholders Equity FY 2025 · Mar 31, 2025 $66.61M
Stockholders Equity FY 2025 · Mar 31, 2024 $61.74M
Stockholders Equity FY 2025 · Mar 31, 2023 $67.96M
Current Liabilities FY 2025 · Mar 31, 2025 $1.93M
Current Liabilities FY 2025 · Mar 31, 2024 $1.68M
Total Liabilities FY 2025 · Mar 31, 2025 $5.38M
Total Liabilities FY 2025 · Mar 31, 2024 $11.56M
Current Assets FY 2025 · Mar 31, 2025 $22.71M
Current Assets FY 2025 · Mar 31, 2024 $24.01M
Total Assets FY 2025 · Mar 31, 2025 $71.99M
Total Assets FY 2025 · Mar 31, 2024 $73.3M
Eps Diluted FY 2025 · Mar 31, 2025 −$0.79
Eps Diluted FY 2025 · Mar 31, 2024 −$1.35
Eps Basic FY 2025 · Mar 31, 2025 −$0.79
Eps Basic FY 2025 · Mar 31, 2024 −$1.35
Sga Expense FY 2025 · Mar 31, 2025 $7.17M
Sga Expense restated FY 2025 · Mar 31, 2024 $6.68M
Rd Expense FY 2025 · Mar 31, 2025 $9.51M
Rd Expense FY 2025 · Mar 31, 2024 $4.68M
Net Income FY 2025 · Mar 31, 2025 −$9.57M
Net Income FY 2025 · Mar 31, 2024 −$12.85M
Operating Income FY 2025 · Mar 31, 2025 −$16.68M
Operating Income FY 2025 · Mar 31, 2024 −$12.85M